Lilly signs up to $1.3 billion deal with Superluminal Medicines to develop obesity medicines

Reuters
Aug 14
Lilly signs up to $1.3 billion deal with Superluminal Medicines to develop obesity medicines

Aug 14 (Reuters) - Eli Lilly LLY.N has signed a deal worth up to $1.3 billion with privately held Superluminal Medicines to discover and develop drugs targeting cardiometabolic diseases and obesity, Superluminal said on Thursday.

(Reporting by Mariam Sunny in Bengaluru; Editing by Pooja Desai)

((Mariam.ESunny@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10